EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Assessment of merozoite surface protein-1 antibodies and anaemia severity in various treatment stages of a nutrananosphere artemisinin-bioflavonoid antimalarial therapy

Olufemi Emmanuel Akanni, Oluwaseyi Eunice Bamisaye, Bukola Patience Opegbemi, Olayinka Christiana Sokunbi, Akeem Ademola Ayankunle, Oyebode Armstrong Terry Alli, Jerry Thomas Thornthwaite

Bio-Research · 18.10.2024 · 22 (2) · 2406-2419

DOI: 10.4314/br.v22i2.10 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bio-Research, online erschienen am 18.10.2024. Verfasst von Olufemi Emmanuel Akanni und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artemisinin-based combination therapy (ACT) effectively treats uncomplicated malaria, but treatment failures and resistance occur in some regions. This study is to assess the merozoite surface protein antibodies and anemia development in an artemisinin-bioflavonoid antimalaria. Seventy-seven individuals, comprising forty-two adults and thirty-five children diagnosed with malaria, were recruited from a primary health care facility in Osun state, Nigeria. Following treatment with the TriAntiMalTM NutraNanosphere, blood samples were collected on days 0, 3, 7, and 16 (D0, D3, D7, and D16) and analyzed for malaria parasite density, anti-MSP-1, and anaemia indicators; Hb, HCT, MCV, MCH and MCHC using thick and thin film examination by WHO-certified microscopists; ELISA and Sysmex K2ZIN autoanalyser respectively. Statistical analyses were conducted using SPSS version 20, with a p-value ≤0.05 considered significant. Anti-MSP-1 levels declined significantly over time; malaria parasite density values decreased from day 0 (103.04±39.04) to day 3 (93.77±36.98), 7 (81.46±30.4), and 16 (67.72±34.53) respectively. Participants with severe anaemia with various anti-MSP-1 concentration decreased from 14.3% (5 subjects) to 2.8% (1 subject) in children and 7.1% (3 subjects) to 2.1% (1 subject) in adults respectively by day 3. Their hematological parameters improved significantly by days 7 and 16 from anaemic state seen in some subjects to normal condition. The decline in MSP-1 antibodies, reduction in parasite density, and improved hematological parameters indicate TriAntiMalTM efficacy. The potential link between MSP-1 antibodies and anaemia severity underscores the complex nature of the host immune response in malaria pathogenesis.

Zitieren

APA

Akanni, O. E., Bamisaye, O. E., Opegbemi, B. P., Sokunbi, O. C., Ayankunle, A. A., Alli, O. A. T., & Thornthwaite, J. T. (2024). Assessment of merozoite surface protein-1 antibodies and anaemia severity in various treatment stages of a nutrananosphere artemisinin-bioflavonoid antimalarial therapy. Bio-Research, 22(2), 2406-2419. https://doi.org/10.4314/br.v22i2.10

Vancouver

Akanni OE, Bamisaye OE, Opegbemi BP, Sokunbi OC, Ayankunle AA, Alli OAT, et al. Assessment of merozoite surface protein-1 antibodies and anaemia severity in various treatment stages of a nutrananosphere artemisinin-bioflavonoid antimalarial therapy. Bio-Research. 2024;22(2):2406-2419. doi:10.4314/br.v22i2.10

BibTeX
@article{Akanni2024,
  author = {Akanni, Olufemi Emmanuel and Bamisaye, Oluwaseyi Eunice and Opegbemi, Bukola Patience and Sokunbi, Olayinka Christiana and Ayankunle, Akeem Ademola and Alli, Oyebode Armstrong Terry and Thornthwaite, Jerry Thomas},
  title = {Assessment of merozoite surface protein-1 antibodies and anaemia severity in various treatment stages of a nutrananosphere artemisinin-bioflavonoid antimalarial therapy},
  journal = {Bio-Research},
  year = {2024},
  volume = {22},
  number = {2},
  pages = {2406--2419},
  doi = {10.4314/br.v22i2.10}
}
Kostenlos starten →